Table 3. Percent Change (95% Confidence Interval)^a in Plasma Inflammation Biomarker in Association with Interquartile Range Increase in Urinary Phthalate Metabolite Concentration.

	CRP		IL-1β		IL-6
	%Δ (95% CI)	p	%Δ (95% CI)	p	%Δ (95% CI)	p
MEHP	8.55 (−7.27, 27.1)	0.31	5.41 (−12.0, 26.3)	0.57	15.9 (−4.58, 40.8)	0.14
MEHHP	4.13 (−9.33, 19.6)	0.57	5.31 (−9.93, 23.1)	0.52	15.8 (−2.23, 37.2)	0.09
MEOHP	4.14 (−9.55, 19.9)	0.57	5.91 (−9.68, 24.2)	0.48	16.9 (−1.57, 38.9)	0.08
MECPP	4.25 (−9.95, 20.7)	0.58	8.06 (−8.37, 27.4)	0.36	18.8 (−0.59, 42.1)	0.06
MCPP	13.0 (−1.23, 29.4)	0.08	–4.50 (−18.1, 11.3)	0.56	2.87 (−13.0, 21.7)	0.74
MCOP	4.21 (−9.48, 20.0)	0.57	6.12 (−9.78, 24.8)	0.48	2.61 (−13.9, 22.3)	0.77
MCNP	10.1 (−0.86, 22.2)	0.08	10.4 (−1.93, 24.3)	0.11	16.8 (2.69, 32.9)	0.02
MBzP	–1.67 (−16.7, 16.1)	0.84	–11.6 (−26.7, 6.55)	0.20	–1.50 (−19.8, 21.0)	0.89
MBP	9.68 (−5.18, 26.9)	0.22	0.97 (−14.4, 19.1)	0.91	–0.73 (−17.1, 18.8)	0.94
MiBP	1.79 (−11.6, 17.3)	0.81	–0.04 (−14.9, 17.3)	1.00	–1.15 (−17.0, 17.7)	0.90
MEP	–2.22 (−18.4, 17.1)	0.81	–3.69 (−21.9, 18.7)	0.73	7.70 (−14.0, 34.9)	0.52

	IL-10		TNF-α
	%Δ (95%CI)	p	%Δ (95%CI)	p
MEHP	17.2 (−2.36, 40.7)	0.09	4.51 (−4.34, 14.2)	0.33
MEHHP	15.8 (−1.10, 35.7)	0.07	4.13 (−3.38, 12.2)	0.29
MEOHP	17.6 (0.18, 38.1)	0.05	4.48 (−3.16, 12.7)	0.26
MECPP	24.5 (5.53, 46.9)	0.01	4.90 (−3.00, 13.5)	0.24
MCPP	2.63 (−12.3, 20.1)	0.75	–0.13 (−7.32, 7.62)	0.97
MCOP	18.0 (0.02, 39.2)	0.05	1.42 (−6.53, 10.0)	0.74
MCNP	7.73 (−4.54, 21.6)	0.23	0.26 (−5.21, 6.03)	0.93
MBzP	–17.8 (−31.9, −0.75)	0.05	1.31 (−7.70, 11.2)	0.78
MBP	–8.28 (−22.4, 8.33)	0.31	3.54 (−4.35, 12.1)	0.39
MiBP	–5.02 (−19.3, 11.8)	0.54	2.54 (−5.10, 10.8)	0.53
MEP	–7.50 (−25.3, 14.5)	0.48	1.91 (−8.35, 13.3)	0.73

^aEstimates created from linear mixed models with random slopes for subject ID and adjustment for urinary specific gravity, visit of sample collection, and maternal prepregnancy BMI, education, and income level. N = 87 subjects; N = 157 observations.